The anti-CD133 antibody-conjugated SN-38-loaded nanoparticles named CD133Ab-NPs-SN-38 has been designed to target CD133+ cells in colorectal cancer, and the results indicated that it could eliminate and suppress cancer growth and recurrence in an HCT116 xenograft model (134). Here, PROM1 is linked to colorectal cancer.